Protective cardiorenal effects of spironolactone in a rodent model of polycystic kidney disease.

@article{Jeewandara2015ProtectiveCE,
  title={Protective cardiorenal effects of spironolactone in a rodent model of polycystic kidney disease.},
  author={Thamarasee M Jeewandara and Omar Z. Ameer and Rochelle Boyd and Benjamin F Wyse and Conor F Underwood and Jacqueline K. Phillips},
  journal={Clinical and experimental pharmacology & physiology},
  year={2015},
  volume={42 4},
  pages={353-60}
}
Studies were performed to examine the contribution of aldosterone to the pathogenesis of cardiovascular and renal disease in a rodent model of genetic kidney disease. Spironolactone (20 mg/kg per day) was administered in water to mixed sex Lewis Polycystic Kidney (LPK) rats (n = 20) and control Lewis rats (n = 27) from 4 to 12 weeks of age. At 12 weeks of age, hypertension was reduced in female LPK rats; systolic blood pressure declined from 226.4 ± 26.8 mmHg in untreated rats and to 179.2 ± 3… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS